BrainStorm Cell Therapeutics is an American biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS). Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
BrainStorm Cell Therapeutics news
16.05.2022
BrainStorm Cell Therapeutics' GAAP loss for 3 months of 2022 was $5.36 million, down 19.5% from $6.662 million in the previous year.
Source: 
ir.brainstorm-cell.com
ir.brainstorm-cell.com
28.03.2022
BrainStorm Cell Therapeutics' GAAP loss for 2021 was $24.457 million, down 23.1% from $31.811 million the previous year.
Source: ir.brainstorm-cell.com
ir.brainstorm-cell.com
15.11.2021
BrainStorm Cell Therapeutics' GAAP loss for 9M 2021 was $18.267 million, down 8.6% from $19.996 million in the prior year.
Source: ir.brainstorm-cell.com
ir.brainstorm-cell.com
05.08.2021
BrainStorm Cell Therapeutics' GAAP loss for 6 months of 2021 was $12.931 million, down 16.6% from $15.508 million in the prior year.
Source: ir.brainstorm-cell.com
ir.brainstorm-cell.com
General information
| Company name | BrainStorm Cell Therapeutics |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 1325 Avenue of Americas Suite 320 New York, NY 10019 United States |
| Mailing address | 1325 Avenue of Americas Suite 320 New York, NY 10019 United States |
| Website | ir.brainstorm-cell.com |
| Information disclosure | www.sec.gov |
English (US) 